ESCRS 2023: New artificial intelligence integrations are ahead for iCare


The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

Artificial intelligence (AI) was a popular topic at this year’s European Society of Cataract and Refractive Surgeons (ESCRS) meeting. At the meeting, our team stopped by the iCare booth to see how AI is improving diagnostic speed and accuracy, for patients of all ages.

Editor's note: The below transcript has been lightly edited for clarity.

Kasperi Kankare: I'm Kasperi Kankare. I'm a key account manager at iCare Finland.

iCare has brought to the ESCRS this year 3 fantastic and unique solutions. We brought something new to glaucoma, we have brought the new iCare IC200, which is faster than ever and with its new quick measurement mode, it also enables measuring paediatric patients, from infants to the grownups, in a 200-degree angle, a complete freedom. Also we have iCare home, which enables the patient to do a home tonometry, which then can deliver the true intraocular pressure value to ophthalmologists and caregivers. And most importantly for glaucoma, we have now brought the new COMPASS. It delivers [an] absolutely fantastic visual field examination within just 4 minutes without [a] trial lens. I would enable the combined COMPASS with the iCare home. Because how you can treat glaucoma without knowing the true intraocular pressure of the patient?

On retina, iCare has always been leading a retina camera manufacturer. Our proprietary true color technology delivers a clear, high contrast image. The iCare ILLUME is the perfect marriage of our DRSplus fully-automatic retinal imaging solution, combined with a cloud service and artificial intelligence, which enables a caregiver to do a patient screening for 3 pathologies: diabetic retinopathy, AMD and glaucoma. Within a time period of 3 minutes from the imaging to the AI report. We have a lot of new interesting things upcoming. What I personally am awaiting most is to work with the artificial intelligence in ILLUME, because that is truly game-changing in our field.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.